Preventives Versus Treatments Redux: Tighter Bounds on Distortions in Innovation Incentives with an Application to the Global Demand for HIV Pharmaceuticals
---- Acknowledgments ----
The authors are grateful to the editor, Victor Tremblay, and anonymous reviewers for suggestions that substantially improved the paper; to Margaret Kyle, Paul Novosad, Douglas Staiger, Robert Staiger, Heidi Williams, and seminar participants at Penn State for insightful comments; and to Matthew Goodkin-Gold and Henry Senkfor for excellent research assistance. Henry Senkfor’s assistantship was funded by Dartmouth College’s Presidential Scholars program, which the authors gratefully acknowledge. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research.